Search

Displaying results 2861 - 2870 of 10000 in total
  1. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    [A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by

  2. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.

  3. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    [A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome

    Synonyms: 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane
  4. Drug

    Norgestrel

    go.drugbank.com/drugs/DB09389
    Approved

    Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only t...

    Mixtures: CYCLO-PROGYNOVA 2 MG+2 MG/0.5 MG KAPLI TABLET, 21 ADET
  5. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  6. Drug

    MM-111

    go.drugbank.com/drugs/DB17983
    Investigational

    MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.

  7. Drug

    Nelistotug

    go.drugbank.com/drugs/DB19334
    Investigational

    NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

    Synonyms: CH1 K120, CH3 D12, L14 (CH1 K120 (219) (123-220), hi, Gamma1 heavy chain Homo sapiens (1-452) [VH(Homo sapiens IGHV1-69*01 (95.9%) -(IGHD)-IGHJ1*01 (90.9%) L123>T (117), CDR-IMGT [8.8.15](26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*01 (100%), G1m17,1
  8. Drug

    Phosphate ion

    go.drugbank.com/drugs/DB14523
    Investigational

    Mixtures: PERIOLIMEL N4-600E İNFÜZYONLUK ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ VE LİPİD EMÜLSİYONU, 2000 ML, NUTRIFLEX LIPID PLUS INFUZYONLUK EMULSIYON, 2500 ML
  9. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.

  10. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.